Apellis Pharmaceuticals Dividends
| APLS Stock | USD 21.81 0.18 0.82% |
Dividends Paid is likely to drop to about 258.3 M in 2026. Dividend Paid And Capex Coverage Ratio is likely to drop to -263.27 in 2026. Apellis Pharmaceuticals' past performance could be the main factor of why investors trade Apellis Pharmaceuticals stock today. Investors should clearly understand every aspect of the Apellis Pharmaceuticals dividend schedule, including its future sustainability, and how it might impact an overall investment strategy. This tool is helpful to digest Apellis Pharmaceuticals' dividend schedule and payout information. Apellis Pharmaceuticals dividends can also provide a clue to the current valuation of Apellis Pharmaceuticals.
| Last Reported | Projected for Next Year | ||
| Dividends Paid | 290.6 M | 258.3 M | |
| Dividend Paid And Capex Coverage Ratio | (250.73) | (263.27) |
Investing in stocks that pay dividends is one of many strategies that are good for long-term investments. Ex-dividend dates are significant because investors in Apellis Pharmaceuticals must own a stock before its ex-dividend date to receive its next dividend.
Apellis Pharmaceuticals Dividends Paid Over Time
Today, most investors in Apellis Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Apellis Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's dividends paid growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Apellis Pharmaceuticals dividends paid as a starting point in their analysis.
The total amount of dividends that a company has paid out to its shareholders over a specific period. Dividends Paid |
| Timeline |
Is there potential for Biotechnology market expansion? Will Apellis introduce new products? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.36 | Revenue Per Share | Quarterly Revenue Growth 1.33 | Return On Assets | Return On Equity |
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Apellis Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Apellis Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Apellis Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.